- $31.73m
- $72.46m
- $26.55m
Brief: Celularity Agree With AD Ports For Exclusive Product Distribution In GCC And Egypt
Brief: Celularity Announces Agreement With Ad Ports Group For Exclusive Product Distribution In Various Territories In The Gulf Cooperation Council Regions And Egypt
Brief: Celularity Inc Says Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank Or Signature Bank
Celularity Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Celularity Receives Preliminary Assessment Of Product Classification And Jurisdiction For Its Investigational Celularity Tendon Wrap (CTW)
Brief: Celularity CEO Robert Hariri To Temporarily Suspend Payment Of Salary Pursuant To Employment Agreement
Brief: Celularity Completes Strategic Review Of 2023 Initiatives
Brief: Celularity And Ch Trading Group Announce Territory Distribution Agreement For The Middle East
Brief: Celularity Appoints Paul Graves As Chief Communications Officer
Brief: Celularity Announces Halal Certification Of Its Advanced Cellular Therapeutics, Biomaterial Products And Business Model
Celularity Inc reports results for the quarter ended in September - Earnings Summary
Brief: Celularity Reports Third Quarter 2022 Financial Results And Provides Corporate Update
Brief: Celularity Promotes Two Executives In Executive Leadership Team
Brief: Celularity Appoints Adrian Kilcoyne As Chief Medical Officer
Rare earth miner NioCorp to merge with Nasdaq-listed blank check firm
Brief: Celularity Inc - Entered Into At-The-Market Sales Agreement Relating To Offer Of Shares Of Class A Common Stock From Time To Time Of Up To $150 Million
Brief: Celularity Inc Files For Mixed Shelf Of Up To $450 Million – SEC Filing
Brief: Celularity Reports Q2 Earnings Per Share $0.32
Brief: Celularity Announces Treatment Of First Patient In Phase 1/2A Clinical Trial For Nk Cell Therapy Cynk-101, In Development For The First-Line Treatment Of Advanced Her2 Positive Gastric And Gastroesophageal Junction (G/Gej) Cancers